Wu Ann Chen, Butler Melissa G, Li Lingling, Fung Vicki, Kharbanda Elyse O, Larkin Emma K, Vollmer William M, Miroshnik Irina, Davis Robert L, Lieu Tracy A, Soumerai Stephen B
1 Center for Child Health Care Studies, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School.
Ann Am Thorac Soc. 2015 Feb;12(2):161-6. doi: 10.1513/AnnalsATS.201410-459OC.
Few previous studies have evaluated primary adherence (whether a new prescription is filled within 30 d) to controller medications in individuals with persistent asthma.
To compare adherence to the major controller medication regimens for asthma.
This was a retrospective cohort study of enrollees from five large health plans. We used electronic medical data on patients of all ages with asthma who had experienced an asthma-related exacerbation in the prior 12 months. We studied adherence measures including proportion of days covered and primary adherence (first prescription filled within 30 d).
Our population included 69,652 subjects who had probable persistent asthma and were prescribed inhaled corticosteroids (ICSs), leukotriene antagonists (LTRAs), or ICS/long-acting β-agonists (ICS/LABAs). The mean age was 37 years and 58% were female. We found that 14-20% of subjects who were prescribed controller medicines for the first time did not fill their prescriptions. The mean proportion of days covered was 19% for ICS, 30% for LTRA, and 25% for ICS/LABA over 12 months. Using multivariate logistic regression, subjects prescribed LTRA were less likely to be primary adherent than subjects prescribed ICS (odds ratio, 0.82; 95% confidence interval, 0.74-0.92) or ICS/LABA (odds ratio, 0.88; 95% confidence interval, 0.80-0.97). Black and Latino patients were less likely to fill the prescription compared with white patients.
Adherence to controller medications for asthma is poor. In this insured population, primary adherence to ICSs was better than to LTRAs and ICS/LABAs. Adherence as measured by proportion of days covered was better for LTRAs and ICS/LABAs than for ICSs.
既往很少有研究评估持续性哮喘患者对控制药物的初始依从性(新处方是否在30天内配药)。
比较哮喘主要控制药物治疗方案的依从性。
这是一项对来自五个大型健康计划参保者的回顾性队列研究。我们使用了所有年龄哮喘患者的电子医疗数据,这些患者在过去12个月内经历过与哮喘相关的加重发作。我们研究了包括覆盖天数比例和初始依从性(首次处方在30天内配药)在内的依从性指标。
我们的研究人群包括69652名可能患有持续性哮喘且被处方吸入性糖皮质激素(ICS)、白三烯拮抗剂(LTRA)或ICS/长效β受体激动剂(ICS/LABA)的受试者。平均年龄为37岁,58%为女性。我们发现,首次被处方控制药物的受试者中有14% - 20%未配药。在12个月期间,ICS的平均覆盖天数比例为19%,LTRA为30%,ICS/LABA为25%。使用多因素逻辑回归分析,与被处方ICS的受试者相比,被处方LTRA的受试者初始依从性较低(比值比,0.82;95%置信区间,0.74 - 0.92),与被处方ICS/LABA的受试者相比也是如此(比值比,0.88;95%置信区间,0.80 - 0.97)。与白人患者相比,黑人和拉丁裔患者配药的可能性较小。
哮喘控制药物的依从性较差。在这个参保人群中,ICS的初始依从性优于LTRA和ICS/LABA。以覆盖天数比例衡量的依从性,LTRA和ICS/LABA优于ICS。